Glenmark Pharmaceuticals Ltd. is an integrated, research–led, global pharmaceutical company, with a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.
The company has 10 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries.
In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2021; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2021. The organization has impacted over 2.9 million lives over the last decade through its CSR interventions
Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led, integrated, global pharmaceutical company has received the final approval from the United States Food & Drug Administration (U.S. FDA) for Tacrolimus Ointment, 0.03%, the generic version of Protopic1 Ointment, 0.03%, of Leo Pharma AS. Glenmark’s Tacrolimus Ointment, 0.03%, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.
According to IQVIATM sales data for the 12-month period ending June 2023, the Protopic Ointment, 0.03% market2 achieved annual sales of approximately $15.4 million*.
Glenmark’s current portfolio consists of 184 products authorised for distribution in the U.S. marketplace and 51 ANDAs pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
